Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52 ‐Week Phase 3 Randomized Study Results

ConclusionSB5 was well tolerated over 1 year in patients with RA with comparable efficacy, safety, and immunogenicity to ADA. Switching from ADA to SB5 had no treatment‐emergent issues such as increased adverse events, increased immunogenicity, or loss of efficacy.This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fart.40444

Source: Arthritis and Rheumatism - February 13, 2018 Category: Rheumatology Authors: Michael E. Weinblatt, Asta Baranauskaite, Eva Dokoupilova, Agnieszka Zielinska, Janusz Jaworski, Artur Racewicz, Margarita Pileckyte, Krystyna Jedrychowicz ‐Rosiak, Inyoung Baek, Jeehoon Ghil Tags: Full Length Source Type: research